Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 0.13% 1,518.50 1,523.00 1,524.00 1,539.00 1,511.50 1,521.00 1,725,893 16:35:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,335.3 179.9 37.5 41.9 13,297

Smith & Nephew Share Discussion Threads

Showing 701 to 724 of 975 messages
Chat Pages: 39  38  37  36  35  34  33  32  31  30  29  28  Older
DateSubjectAuthorDiscuss
09/5/2016
07:31
Jefferies International Smith & Nephew PLC 09/05/2016 Upgrades Hold Buy 2 1,044.00 1,375.00 1,136.00 331 2
broadwood
08/3/2016
07:26
Stryker making new highs while SN lag somewhat toward 1100p. Frustrating, should be through 1200p really. Bid possible anytime.
its the oxman
04/2/2016
07:11
Those a very solid final figures.
steeplejack
20/1/2016
08:26
Looks like it hit £10 sooner then you think!!!!!!
scoble2
04/1/2016
08:43
30p down may be no takeover?
scoble2
31/12/2015
10:33
Hello, anyone listening?
blocker2
31/12/2015
10:15
I am out and took my profit.
scoble2
31/12/2015
08:11
No news of takeover disappointed - time to take some profit?
scoble2
29/12/2015
15:29
Takeover news is imminent
scoble2
29/12/2015
13:20
Takeover rumour again £13.75?
scoble2
23/12/2015
12:08
Olivier and his cronies are going mental with re-organisation too.
knighty0001
22/12/2015
10:51
Medical play shoots skywards Prosthetic joint builder Smith & Nephew (LSE: SN) has also enjoyed a splendid bump higher during the past week, the stock having added 9% between Monday and Friday. And I believe the London business can continue pulling away from its recent 12-month lows as growth investors pile in. Smith & Nephew received a shot in the arm last week thanks to rumours that Stryker was poised to launch a £12.1bn takeover attempt. The US-based medical firm is flush with cash and has apparently appointed Goldman Sachs to advise on a potential deal. And I believe Smith & Nephew is certainly worth the fuss. Demand for the company’s synthetic body parts continues to explode, particularly in the white-hot North American market. Meanwhile acquisitions in developed and emerging regions alike should significantly bolster sales in the years ahead. Smith & Nephew is expected to recover from an anticipated 4% earnings fall in 2015 with a 10% rise next year, resulting in a P/E rating of 19.1 times. I believe the firm’s improving position in a rapidly-expanding market fully warrants such a rating.
broadwood
21/12/2015
08:46
Brocker put the takeover value @13.25?
scoble2
20/12/2015
16:47
Smith & Nephew shares boosted by takeover talk - FT.com
scoble2
20/12/2015
16:46
MARKET REPORT: Shares in artificial hip-maker Smith & Nephew perk up on talk of £12.1bn bid from US rival Stryker
scoble2
18/12/2015
16:42
I smell smoke. Long awaited. http://sharecast.com/news/us-based-stryker-set-to-pounce-on-smith-nephew/23747223.html
broadwood
18/12/2015
16:18
Take over rummer £14 / share
scoble2
29/10/2015
08:48
"We expect annual revenue growth at Blue Belt Technologies to be in excess of 50% over the medium-term from a 2015 base of approximately $19 million. Investment in the combined R&D programmes and supportive clinical evidence will dilute Group trading profit margin by around 60bps in 2016, with the business becoming profitable in 2018. Return on capital employed is expected to exceed our weighted average cost of capital in year four."Slightly churlish reaction to a reasonable set of third qtr figures.Adverse currency impact resulting from strong dollar.Disappointment that this smallish acquisition won't be earnings accretive for a number of years.Of course,with Stryker in the wings,maybe the market would have preferred news of a predator stalking S&N rather than an acquisition by the company itself.
steeplejack
14/8/2015
12:31
SN. Smith@Nephew Director cluster BUYING notified today........... Dec. Date Deal. Date Type EPIC Company Director Pos No. of shares Price Value Current price Value now % gain Monetary gain 14/08/2015 13/08/2015 BUY SN. Smith & Nephew Quarta, Roberto CH 4,629 1,188.00 p £54,993 1,175.50 p 54,413.90 -1.05 -579 14/08/2015 13/08/2015 BUY SN. Smith & Nephew Barlow, Ian NED 153 1,188.00 p £1,818 1,175.50 p 1,798.52 -1.05 -19 14/08/2015 13/08/2015 BUY SN. Smith & Nephew Bottomley, Baroness Virginia NED 159 1,188.00 p £1,889 1,175.50 p 1,869.05 -1.05 -20 14/08/2015 13/08/2015 BUY SN. Smith & Nephew Engstrom, Erik NED 140 1,188.00 p £1,663 1,175.50 p 1,645.70 -1.05 -18 14/08/2015 13/08/2015 BUY SN. Smith & Nephew Larcombe, Brian NED 140 1,188.00 p £1,663 1,175.50 p
mike740
09/7/2015
07:42
Berenberg Smith & Nephew PLC 09/07/2015 Upgrades Hold Buy 2 1,080.00 1,275.00 1,086.00 195 2
broadwood
30/4/2015
07:56
Smith & Nephew has booked Q1 revenue of $1,104 million, up 3% on an underlying basis. Reported growth of 3% includes effects of -8% currency headwind offset by 8% benefit from acquisitions. The company's full-year outlook remains unchanged, it said. "We continue to expect to deliver higher underlying revenue growth in 2015 than in 2014 and an improvement in trading profit margin," it said in a statement. "We expect the phasing of revenue and profit to be more pronounced in 2015 than 2014, with profitability in the second half being significantly stronger than the first. "As previously guided we expect a significant currency headwind in 2015. If current exchange rates prevail throughout the year we expect the headwind to be -7% on reported revenue. "We are pleased with our start to 2015 and are on track to make further progress during the year." Referring to the Q1 performance, CEO Olivier Bohuon said: "We are pleased with our start to 2015 and are on track to make further progress during the year. "In particular, we increased Q1 revenue by 22% across the Emerging Markets and delivered 9% growth in Sports Medicine Joint Repair. We completed the integration of ArthroCare and the expected benefits of our strong combined sports medicine portfolio are starting to come through. "In Reconstruction, strong sales of our JOURNEY II Knee System drove 3% growth in US Knee Implants, and, through our actions, we delivered an improved Advanced Wound Care performance." Other highlights: · Strong 9% revenue growth in Sports Medicine Joint Repair, particularly in the US, reflects the continued strengthening of our franchise following the acquisition of ArthroCare · JOURNEY◊ II Total Knee System continues to perform very well, driving 3% US Knee Implant revenue growth · Advanced Wound Care revenue performance improving, up 9% · Continued momentum in Emerging Markets with 22% revenue growth. Latin American presence further strengthened with distributor acquisition in Colombia
broadwood
11/4/2015
10:26
yep, key level.. >>
leeson31
10/4/2015
22:41
Could break 1200p next week.
its the oxman
23/3/2015
14:02
UPGRADE.....23 Mar 2015 Smith & Nephew PLC SN. Goldman Sachs Buy 1,158.50 1,148.00 1,200.00 1,300.00 Upgrades SP TARGET 1300p
mike740
Chat Pages: 39  38  37  36  35  34  33  32  31  30  29  28  Older
ADVFN Advertorial
Your Recent History
LSE
SN.
Smith & Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210518 23:29:10